News
AGIO
29.22
+0.34%
0.10
Weekly Report: what happened at AGIO last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at AGIO last week (0311-0315)?
Weekly Report · 03/18 09:03
Weekly Report: what happened at AGIO last week (0304-0308)?
Weekly Report · 03/11 09:03
Agios Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 03/06 04:21
Weekly Report: what happened at AGIO last week (0226-0301)?
Weekly Report · 03/04 09:03
Weekly Report: what happened at AGIO last week (0219-0223)?
Weekly Report · 02/26 09:03
Agios Pharmaceuticals Price Target Cut to $30.00/Share From $31.00 by JP Morgan
Dow Jones · 02/23 17:44
Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan
Dow Jones · 02/23 17:44
Agios Pharmaceuticals Up Nearly 11%, on Pace for Largest Percent Increase Since September 2022 -- Data Talk
Agios Pharmaceuticals, Inc. Is currently at $29.74, up $2.94 or 10.97%. Company is on pace for largest percent increase since Sept. 8, 2022. Up four of the past six days, up 31.48% month-to-date.
Dow Jones · 02/22 19:10
Weekly Report: what happened at AGIO last week (0212-0216)?
Weekly Report · 02/19 09:03
Optimistic Outlook for Agios Pharma: A Buy Rating Amidst Pyrukynd Sales Miss and Promising ENERGIZE-T Trial Prospects
Despite a recent sales miss for Pyrukynd, Agios Pharma has a positive outlook. Management remains confident in the upcoming ENERGIZE-T trial results. Leerink Partners has maintained their Buy rating on AGIO stock. The company is a biopharmaceutical company developing treatments for rare genetic diseases.
TipRanks · 02/19 04:46
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Agios Pharmaceuticals, Inc. Shares are up 5.4% in the past 7 days after analysts downgraded their forecasts for this year. Revenue and earnings per share forecasts were both revised downwards for the company. The most recent consensus is for revenues of US$43m in 2024. The company's losses per share is expected to increase to US$5.80 per share. Despite the downgrade, the price target for the stock remains unchanged.
Simply Wall St · 02/17 12:16
Agios Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 02/16 17:08
Agios Pharmaceuticals Price Target Cut to $42.00/Share From $43.00 by RBC Capital
Dow Jones · 02/16 17:08
RBC Capital Maintains Outperform on Agios Pharmaceuticals, Lowers Price Target to $42
Benzinga · 02/16 16:58
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
NASDAQ · 02/16 14:38
Buy Rating for Agios Pharma Amid Expanding Drug Pipeline and Strong Commercial Prospects
TipRanks · 02/16 10:08
U.S. RESEARCH ROUNDUP-Nvidia, Albemarle, Dropbox
Wall Street analysts revise ratings and price targets on several U.S. Listed companies. Albemarle, Dropbox and Nvidia revise their ratings and targets on Friday. Deere & Co, Applied Materials and AIG among companies to see price targets cut. Some analysts raise their target prices for the companies.
Reuters · 02/16 09:25
U.S. RESEARCH ROUNDUP-Albemarle, Dropbox, Tyler Technologies
Wall Street analysts revise their ratings and price targets on several U.S. Listed companies. Albemarle, Dropbox, Tyler Technologies and Deere & Co among companies with revised targets. AIG, Crocs, Nvidia and AIG all raise their targets for the day.
Reuters · 02/16 07:19
Buy Rating Justified by Agios Pharma’s Promising Trials and Future Prospects
TipRanks · 02/15 21:05
More
Webull provides a variety of real-time AGIO stock news. You can receive the latest news about Agios Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (LR MDS), and hemolytic anemias.